熱門資訊> 正文
免疫工程报告第一季度结果
2024-05-08 22:50
- Immuneering press release (NASDAQ:IMRX): Q1 GAAP EPS of -$0.49 misses by $0.02.
- Cash, cash equivalents and marketable securities as of March 31 were $71.3M, compared with $85.7M as of December 31, 2023.
- The company expects its cash runway to be sufficient to fund operations into the second half of 2025.
More on Immuneering
- Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
- Seeking Alpha's Quant Rating on Immuneering
- Historical earnings data for Immuneering
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
